An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that activation of PPARs may cause the body to increase its use of fatty acids for energy, and lead to a reduction in body fat. There are also data to suggest a role for PPARs in regulating lipid (e.g., cholesterol) levels and inflammation. These and other activities of PPARs are being further explored in this clinical study.
|Official Title:||A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects|
- Body fat levels
- Levels of multiple proteins/biomarkers in blood and fat tissue, as well as specific lipid in muscle and liver (via imaging). Gene expression in blood and fat tissue.
|Study Start Date:||December 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00388180
|United States, Louisiana|
|GSK Investigational Site|
|Baton Rouge, Louisiana, United States, 70808|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|